Zobrazeno 1 - 10
of 87
pro vyhledávání: '"adverse effects [Levodopa]"'
Publikováno v:
Movement disorders 36(4), 1045-1047 (2021). doi:10.1002/mds.28576
Mov Disord
Mov Disord
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fb786a52d8bf9ee51263b7983def9a8
https://doi.org/10.1002/mds.28576
https://doi.org/10.1002/mds.28576
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism
Autor:
Christoph van Riesen, Christopher Güttler, Saskia Böckmann, Andrea A. Kühn, Jennifer Altschüler, Vadim V. Nikulin, Jens K. Haumesser, Kaloyan S. Tanev
Publikováno v:
Movement disorders 36(4), 927-937 (2021). doi:10.1002/mds.28403
Movement Disorders
Movement Disorders
Background Levodopa is the most efficacious drug in the symptomatic therapy of motor symptoms in Parkinson's disease (PD); however, long‐term treatment is often complicated by troublesome levodopa‐induced dyskinesia (LID). Recent evidence suggest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b834a43345ce1ca81ee64417bfc6ed50
https://pub.dzne.de/record/154332
https://pub.dzne.de/record/154332
Autor:
Wei-Hua Chiu, Thomas Carlsson, Eberhard Weihe, Martin Klietz, Günter U. Höglinger, Candan Depboylu, Ursula Keber, Martin K.-H. Schäfer
Publikováno v:
Neuroscience 331, 120-133 (2016). doi:10.1016/j.neuroscience.2016.06.017
l-3,4-Dihydroxyphenylalanine (l-DOPA) is the therapeutic gold standard in Parkinson's disease. However, most patients develop debilitating abnormal involuntary movements termed l-DOPA-induced dyskinesia (LID) as therapy-complicating side effects. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0246f1945a8c32bf971921001502ab7a
https://doi.org/10.1016/j.neuroscience.2016.06.017
https://doi.org/10.1016/j.neuroscience.2016.06.017
Autor:
Martin K.-H. Schäfer, Eberhard Weihe, Ursula Keber, Günter U. Höglinger, Martin Klietz, Thomas Carlsson, Wolfgang H. Oertel, Candan Depboylu
Publikováno v:
Neuroscience 298, 302-317 (2015). doi:10.1016/j.neuroscience.2015.04.021
L-3,4-Dihydroxyphenylalanine (L-DOPA) is the therapeutic gold standard in Parkinson's disease. However, long-term treatment is complicated by the induction of debilitating abnormal involuntary movements termed L-DOPA-induced dyskinesias (LIDs). Until
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20049f1540beb207c7ba722153abfbc0
https://doi.org/10.1016/j.neuroscience.2015.04.021
https://doi.org/10.1016/j.neuroscience.2015.04.021
Publikováno v:
Current medical research and opinion 28(7), 1239-1246 (2012). doi:10.1185/03007995.2012.702101
Knowledge of patients' treatment needs is an important requirement for comprehensive long-term patient care. The objective of this investigation was to assess the requirements of patients with Parkinson's disease (PD) regarding pharmacotherapy.A tota
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e1898305a0214d24f5b3019dc55b9d
https://doi.org/10.1185/03007995.2012.702101
https://doi.org/10.1185/03007995.2012.702101
Autor:
Scorziello, Antonella1 (AUTHOR) rossana.sirabella@unina.it, Sirabella, Rossana1 (AUTHOR) michele.tufano@unina.it, Sisalli, Maria Josè2 (AUTHOR) mariajose.sisalli@unina.it, Tufano, Michele1 (AUTHOR) lgiacciol@gmail.com, Giaccio, Lucia1 (AUTHOR) elena.dapolito@unina.it, D'Apolito, Elena1 (AUTHOR) lorenzo.castellano@unina.it, Castellano, Lorenzo1 (AUTHOR), Annunziato, Lucio3 (AUTHOR) scorziel@unina.it
Publikováno v:
International Journal of Molecular Sciences. Nov2024, Vol. 25 Issue 21, p11490. 21p.
Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect
Autor:
J. Artur Serrano, Svenja Hucker, Holm Graessner, Yiannos Manoli, Ulrike Braatz, Walter Maetzler, Daniela Berg, Joaquim J. Ferreira, Janet M.T. van Uem, Tanja Heger, Robert Ramsperger, Markus A. Hobert, Stefan Meckler
Publikováno v:
Parkinsonism & related disorders 26, 41-46 (2016). doi:10.1016/j.parkreldis.2016.02.007
Dyskinesias in Parkinson's disease (PD) patients are a common side effect of long-term dopaminergic therapy and are associated with motor dysfunctions, including gait and balance deficits. Although promising compounds have been developed to treat the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2024507411c330ef649712f0d28d315
https://pub.dzne.de/record/138585
https://pub.dzne.de/record/138585
A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia
Autor:
Claudia, Trenkwalder, Daniela, Berg, Olivier, Rascol, Karla, Eggert, Andres, Ceballos-Baumann, Jean-Christophe, Corvol, Alexander, Storch, Lin, Zhang, Jean-Philippe, Azulay, Emmanuel, Broussolle, Luc, Defebvre, Christian, Geny, Michal, Gostkowski, Fabrizio, Stocchi, Christine, Tranchant, Pascal, Derkinderen, Franck, Durif, Alberto J, Espay, Andrew, Feigin, Jean-Luc, Houeto, Johannes, Schwarz, Thérèse, Di Paolo, Dominik, Feuerbach, Hans-Ulrich, Hockey, Judith, Jaeger, Annamaria, Jakab, Donald, Johns, Gurutz, Linazasoro, Paul, Maruff, Izabela, Rozenberg, Judit, Sovago, Markus, Weiss, Baltazar, Gomez-Mancilla
Publikováno v:
Movement disorders 31(7), 1049-1054 (2016). doi:10.1002/mds.26569
This phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson's disease and levodopa-induced dyskinesia.Patients with idiopathic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::87d8f8277e4711a4fd7b611116e0b789
https://pub.dzne.de/record/138662
https://pub.dzne.de/record/138662
Publikováno v:
Journal of Neurochemistry; 84(6), pp 1398-1410 (2003)
We have examined the ability of KW-6002, an adenosine A2a antagonist, to modulate the dyskinetic effects of l-DOPA in 6-hydroxydopamine-lesioned rats. In animals rendered dyskinetic by a previous course of l-DOPA treatment, KW-6002 did not elicit any
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe0b2e30d63e78afe6f634b8139d50fc
https://doi.org/10.1046/j.1471-4159.2003.01632.x
https://doi.org/10.1046/j.1471-4159.2003.01632.x
Autor:
Christian Sass, Daniela Berg, Ralf Reilmann, Inga Liepelt-Scarfone, Walter Maetzler, Eva Schaeffer
Publikováno v:
Journal of neural transmission 122(9), 1271-1278 (2015). doi:10.1007/s00702-015-1383-7
Although Levodopa-induced dyskinesias (LID) are one of the most compromising complications of dopaminergic treatment in Parkinson’s disease (PD), there is no widely accepted assessment tool available that evaluates LID quantitatively. This is of re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f55f5522e09d06401548bf7e0f72bd4c
https://pub.dzne.de/record/138067
https://pub.dzne.de/record/138067